Ditto Bio is a Y Combinator-backed biotechnology startup that discovers new drugs for autoimmune diseases by harnessing parasite biology. Their AI platform identifies therapeutic proteins from viruses, ticks, and worms that have evolved to modulate the immune system over millions of years.
Leveraging millions of years of parasite evolution to discover novel immunomodulatory proteins that can treat autoimmune diseases where the immune system attacks the body.
AI Visibility Score
Ditto Bio has an AI visibility score of 9/100, rated as invisible. This score reflects how often and how prominently Ditto Bio appears in responses from AI assistants like ChatGPT, Claude, and Gemini.
AI Perception Summary
Ditto Bio is currently a ghost in the AI biotech conversation, completely missing from high-intent searches by Big Pharma scouts despite a niche presence in specialized immunology research. While competitors like Exscientia and Recursion dominate the narrative for AI-driven drug discovery, Ditto Bio only surfaces during deep technical inquiries into parasite biology or direct brand vibe checks.
Strengths
- Secured the #1 position in AI Overviews for specialized research queries regarding parasite proteins and autoimmune disease treatment.
- Maintains a high average position (2.5) among Senior Immunology Researchers, suggesting strong technical relevance within a narrow scientific niche.
- Successfully maintains brand control in direct queries, achieving #1 rankings across all platforms when users specifically ask 'What do you know about Ditto Bio?'
Visibility Gaps
- Zero percent mention rate on ChatGPT, the most widely used AI platform for strategic research and industry analysis.
- Complete absence from critical category queries like 'emerging biotech startups' and 'most trusted AI-powered drug discovery platforms.'
- Total failure to reach the Big Pharma Strategic Scout persona, who is currently being steered toward competitors like Exscientia, Roche, and Recursion.
Competitors in AI Recommendations
- Exscientia: 21 mentions
- Recursion Pharmaceuticals: 18 mentions
- Insilico Medicine: 14 mentions
- Atomwise: 12 mentions
- Schrödinger: 12 mentions
- BenevolentAI: 11 mentions
- AlphaFold: 11 mentions
- Roche: 10 mentions
- Generate Biomedicines: 9 mentions
- Bristol Myers Squibb: 9 mentions
- Absci: 9 mentions
- Immunai: 8 mentions
- Sanofi: 8 mentions
- Genentech: 7 mentions
- Eli Lilly: 7 mentions
Categories: Biotechnology
Tags: YC25-26